A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
| Autor: | Svetlana Kobina, Marcus A. Neubauer, Lina Asmar, Charles Weissman, Sharon Pritchard, Craig H. Reynolds |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Lung Neoplasms Organoplatinum Compounds medicine.medical_treatment Deoxycytidine Gastroenterology Carboplatin chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Aged 80 and over First-line Middle Aged Oxaliplatin Survival Rate Treatment Outcome Oncology Tolerability Carcinoma Squamous Cell Metastatic Female Lung cancer medicine.drug Adult Pulmonary and Respiratory Medicine medicine.medical_specialty Paclitaxel GemOx Adenocarcinoma Phase III Internal medicine medicine Chemotherapy Humans Aged Neoplasm Staging business.industry medicine.disease Gemcitabine Surgery Regimen chemistry Cisplatin business Follow-Up Studies |
| Zdroj: | Journal of Thoracic Oncology. 6:358-364 |
| ISSN: | 1556-0864 |
| DOI: | 10.1097/jto.0b013e3181ffe8ef |
| Popis: | Purpose: This phase III study compared the efficacy and tolerability of gemcitabine and oxaliplatin (GEMOX) with paclitaxel and carboplatin (PCb) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer. Patients and Methods: Patients aged 18 years or older were randomized to PCb (paclitaxel 225 mg/m 2 followed by carboplatin area under the curve=6 on day 1 every 3 weeks) or GEMOX (gemcitabine 1,000 mg/m 2 on days 1 and 8 followed by oxaliplatin 130 mg/m 2 on day 1 every 3 weeks) for up to six cycles. The primary end point was progression-free survival (PFS), with tumor response rate, overall survival (OS), and quality of life as secondary end points. Results: The study was terminated after 383 patients had been randomized (371 received treatment) as the incidence of adverse events had exceeded the protocol-specified safety threshold (≥20% in either arm). No formal statistical comparisons were conducted. Median PFS was 4.44 months and 4.67 months in the GEMOX and PCb groups, respectively. Objective response rates (complete or partial) were 15.2% and 22.4% in the GEMOX and PCb arms, respectively. Median OS was 9.90 months (GEMOX) and 9.24 months (PCb); post hoc analyses showed median OS in patients aged 70 years or older to be similar to those younger than 70 years. PFS was similar in both groups of patients with adenocarcinoma histology, although OS favored the GEMOX group. Quality of life was improved from baseline in both groups. Toxicity profiles were comparable between the groups. Conclusion: PFS, OS, and objective response rates with GEMOX were similar to PCb. Nevertheless, toxicities limit the adoption of this regimen for routine use in advanced non-small cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|